Holen Sie sich die Stockscreener-App
5.91
3.90%
-0.24
Handel nachbörslich:
29.72
23.81
+402.88%
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Mizuho reiterates Relmada stock rating on positive cancer trial data - Investing.com
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' - StreetInsider
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data - Yahoo Finance
RLMD Shares Jump 42% Over the Past Week: Key Information You Need - Bitget
RLMD Stock Surges 42% in a Week: Here's What You Should Know - TradingView
Relmada reports 76% response rate for bladder cancer therapy - Investing.com Nigeria
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Biotech Relmada schedules March 19 call on Q4 2025 results - Stock Titan
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference - 富途牛牛
Relmada Therapeutics (NASDAQ:RLMD) Shares Gap DownTime to Sell? - MarketBeat
Relmada Therapeutics at Leerink Global: Strategic Shift to Uro-Oncology By Investing.com - Investing.com Canada
A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement - Yahoo Finance
Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer - Indian Pharma Post
A Look At Relmada Therapeutics (RLMD) Valuation After NDV‑01 Phase 2 Bladder Cancer Data - Sahm
Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01 - TipRanks
Relmada reports 76% response rate for bladder cancer therapy By Investing.com - Investing.com Canada
Relmada Therapeutics (RLMD) Stock Jumps 31% on Breakthrough Bladder Cancer Data - MEXC
Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month HighShould You Buy? - MarketBeat
Relmada Therapeutics Announces 76% 12-Month Complete Response Rate in Phase 2 NDV-01 Trial for High-Risk Non-Muscle Invasive Bladder Cancer - Minichart
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
Mizuho reiterates Relmada stock rating on bladder cancer trial data By Investing.com - Investing.com UK
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data - Intellectia AI
Relmada Therapeutics Gains Attention with Promising Bladder Cancer Asset - timothysykes.com
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing - Investing News Network
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer - Investing News Network
Relmada Therapeutics (RLMD) Stock Surges as Bladder Cancer Trial Shows 76% Response Rate - MEXC
Relmada Therapeutics jumps on NDV-01 12-month Phase 2 data and $160M private placement - Quiver Quantitative
Relmada Therapeutics, Inc. announced that it expects to receive $159.999996 million in funding from a group of investors - marketscreener.com
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Mizuho reiterates Relmada stock rating on bladder cancer trial data - Investing.com
Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3 - Bez Kabli
Why Is RLMD Stock Surging Premarket? NDV-01 Trial Update and $160M PIPE Deal - Tokenist
Why Is Relmada Therapeutics Stock Soaring Monday? - Bitget
Relmada Therapeutics (RLMD) Stock Jumps 31% on Promising Bladder Cancer Data - parameter.io
Relmada Therapeutics (RLMD) Stock Jumps 31% on Promising Bladder Cancer Data and $160M Financing - MoneyCheck
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - Asianet Newsable
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) following "home run with the 12-month data" - StreetInsider
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Is Relmada Therapeutics Stock (RLMD) Up Today? - TipRanks
Relmada Therapeutics (RLMD) Secures $160M through PIPE Financing - GuruFocus
Relmada Therapeutics secures $160M in PIPE financing - Investing.com
Relmada Therapeutics prices 29.47M shares at $4.75 in private placement - TipRanks
Relmada Therapeutics (RLMD) Reports Promising 12-Month Data for NDV-01 Trial - GuruFocus
Relmada Therapeutics Raises Capital, Highlights Promising NDV-01 Data - TipRanks
Relmada Therapeutics recently announced positive data for its investigational drug NDV-01 in high-risk non-muscle invasive bladder cancer. - Bitget
Relmada Therapeutics stock surges 25% on bladder cancer data By Investing.com - Investing.com Australia
Relmada Therapeutics stock surges 25% on bladder cancer data - Investing.com
Relmada Therapeutics Raises $160 Million in Private Placement of Stock and Pre-Funded Warrants - TradingView
Experimental bladder cancer therapy NDV-01 achieves 76% 1-year complete response - Stock Titan
Relmada Therapeutics recently disclosed that its phase 3 second-line study targeting BCG non-responsive patient groups is expected to yield preliminary 3-month efficacy data by the end of 2026. - Bitget
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):